DOT1L

Across TCGA pan-cancer cohorts, DOT1L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DOT1L data layer compared with 29 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher DOT1L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DOT1L expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where DOT1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.924	0.719	.008	8	view →
PDAC	DFS	Tertile	II,III,IV	0.230	0.644	.020	4	view →
LUAD	OS	Median	III,IV	0.454	0.766	.039	2	view →
HNSC	OS	Tertile	II,III,IV	0.837	0.575	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DOT1L–LSCC (OS)

Open the LSCC breakdown →